• One in five (21%) organizations have experienced an increase in safety incidents as a result of a poor hire
• 73% say they feel under pressure to hire quickly, resulting in rushed recruitment decisions
• Hirers increasingly demanding transferable skills such as attention to detail, problem-solving and communication, as well as technical skills
• Talogy launches I-Grade suite of solutions to help industrial organizations screen and select good candidates based on job-specific and transferable skills

GLENDALE, Calif., Aug. 27, 2025 /PRNewswire/ — New research has found that decreased productivity, poor work quality and an increase in safety incidents are some of the costly consequences of hiring the wrong people for entry-level roles in the industrial sector.

The study – ‘Quality hires, quality output: Smart talent strategies for industrial hiring’ – from talent management solution provider, Talogy, investigated the challenges of hiring employees with the right mix of both technical and transferable skills to fulfil entry-level roles.

It surveyed 855 industrial hiring professionals in sectors such as manufacturing, construction, logistics, distribution, transportation, energy, warehousing, utilities, automotive and engineering.

With a skills shortage impacting many of these industries, the report found that a significant proportion of hirers – 73% – felt under pressure to hire quickly, but were seeing the consequences of rushed recruitment decisions.

More than half (51%) of respondents reported increased costs due to rehiring or training, particularly where transferable skills were lacking, while nearly two thirds (63%) saw decreased productivity and 56% reported poor work quality.

Most concerningly, one in five (21%) said their organization had experienced an increase in safety incidents as a result of a poor hire.

As a result, 85% of survey respondents believe that hiring for quality and skill readiness is becoming increasingly critical, particularly with advancements in technology impacting multiple industrial sectors.

Trevor McGlochlin, Managing R&D Consultant from Talogy, commented:

“In the industrial labor market, competition for entry-level talent remains high, and finding the right people to fulfil frontline roles is increasingly challenging. It is therefore not surprising that many employers rush to make quick hiring decisions, without potentially going through the right process.”

“However, this research reveals that prioritizing speed of hire over quality can be hugely detrimental. These are often sectors where employee performance directly impacts safety, productivity, and efficiency, and the fact that many of our respondents could directly link safety incidents to a poor hire is very worrying.”

“This is why quality is so important. A strong hire brings the right technical and transferable skills, as well as mindset, which reduces errors, minimizes downtime, and supports continuous improvement. This research shows the bottom-line impact of poor hires, which can significantly hurt output and profitability.”

The top four missing skills

Of the skills most commonly lacking in new hires, the research revealed that the top four were:

• attention to detail
• problem-solving
• communication
• advanced technical skills.

This showcases that transferable skills, as well as job-specific skills, are becoming an increasingly important factor in recruitment success.

Trevor McGlochlin continues:

“Industrial jobs are often shift-based, physically demanding, and require consistency, teamwork, and safety-mindedness. So, while a candidate may meet the basic technical requirements, if they don’t have qualities such as reliability, resilience, and attention to detail, candidates will be ABLE to do the job but are less likely to actually DO the job.”

“With technology changing so rapidly, recruiting people who have both technical and transferable skills is clearly a priority. These are skills that not only serve them well in their specific role but demonstrate future capabilities and agility.”

To support employers in the industrial sector to make informed hiring decisions, Talogy’s I-Grade (Industrial-Grade) suite of solutions are proven to help the sector hire more efficiently and effectively.

It includes screening and selection solutions that assess job-specific and transferable skills,providing data backed insights to ensure organizations are getting the right person for the role and their company. Using highly interactive simulations that keep candidates engaged from start to finish – from production simulations and hands-on assessments, to SJTs, and interactive safety modules – Talogy I-Grade is designed specifically to reduce drop-out rates and increase quality of hire.

For more information visit talogy.com/TalogyIGrade

IMAGES:

Industrial hiring
Industrial work

• New sour cream cups with 30% recycled content to be available in many ALDI SÜD stores
• This collaboration reflects growing industry shift toward circular polystyrene food-contact packaging

FRANKFURT, Germany, Aug. 27, 2025 /PRNewswire/ — INEOS Styrolution has launched its latest circular packaging breakthrough: sour cream cups made with 30% recycled polystyrene, available in ALDI SÜD stores across Germany since the beginning of this year. Developed in collaboration with development partner ALDI SÜD and Unternehmensgruppe Theo Müller, this marks a major step forward in scaling sustainable food packaging for mass-market use. In July 2025, these sour cream cups were recognised with the German Packaging Award in the “Sustainability: recycled content” category.

This is the second commercial roll-out of food-grade recycled polystyrene by INEOS Styrolution with a leading German retailer, reinforcing its position as a frontrunner in the race to decarbonise packaging.

“INEOS Styrolution is turning the promise of recycled polystyrene into a practical reality,” said Rob Buntinx, President EMEA. “We’re proving that circular solutions can meet both food safety standards and performance demands. We’re calling on the entire value chain to join us in making circularity the new normal.”

This move comes as the packaging industry prepares for stricter EU rules under the Packaging and Packaging Waste Regulation (PPWR). INEOS Styrolution has already submitted a formal EFSA application for its novel recycling technology underscoring its commitment to regulatory compliance and innovation.

With multiple food-grade applications already on the market and more to follow, INEOS Styrolution is helping drive a fundamental shift: from single-use plastics to scalable, circular solutions fit for the future.

About INEOS Styrolution 

INEOS Styrolution is the number one producer of high-performance styrenics, offering a broad portfolio that comprises styrene monomer, polystyrene, ABS, and advanced styrenics. The company delivers customised solutions for customers across automotive, healthcare, electronics, household, construction, packaging, toys, sports and leisure sectors. With more than 90 years of innovation in material science and 16 production sites worldwide, INEOS Styrolution combines global reach with local expertise to meet the evolving needs of its customers. This includes bringing safe, sustainable, and high-performing products to market and supporting their efforts toward meeting their sustainability targets.

INEOS Styrolution is fully owned by INEOS Group.

For further information, please visit: www.ineos-styrolution.com

DONGGUAN, China, Aug. 27, 2025 /PRNewswire/ — vivo, a global leader in mobile technology, celebrates its 30th anniversary, marking three decades of technological leadership, user-centric innovation, and global impact. Since its establishment in 1994, vivo has been at the forefront of mobile innovation, delivering cutting-edge products that enhance connectivity and digital experiences worldwide.

In 2019, the company’s commitment to breakthrough technology led to the creation of its sub-brand, iQOO, extending vivo’s legacy of innovation into high-performance gaming and premium smartphone segments. iQOO continues to embody vivo’s core values of innovation and user-focused design.

As part of its anniversary celebration, vivo has unveiled the groundbreaking vivo Vision Discovery Edition, showcasing the company’s advanced capabilities in spatial computing and immersive technology. Representing vivo’s strongest technological achievement in extended reality, The headset is the first MR product developed by a smartphone manufacturer in China, positioning vivo as the first Chinese company to operate within both the smartphone and MR product sectors. Designed for daily use, this cutting-edge device features a lightweight, ergonomically optimized build. Weighing just 398g with a height of 83 mm and a thickness of 40 mm, it is 26% smaller than the industry average, improving overall comfort. Informed by extensive human factors research, the design offers four sizes of light seal, and eight foam padding options to ensure an optimal fit and long-lasting comfort, even during extended wear or active movement.

“This anniversary marks not just a milestone but a new beginning,” said an iQOO spokesperson. “The vivo Vision Discovery Edition showcases the technological foundation that empowers iQOO to push the boundaries in mobile performance and innovation. We are excited to incorporate these advancements into future iQOO products.”

Looking ahead, iQOO will continue to leverage vivo’s breakthroughs in AI, imaging, and immersive computing to create devices that deliver extreme performance, sleek design, and unparalleled user experiences for tech enthusiasts worldwide.

About iQOO

iQOO is a global technology brand dedicated to developing high-performance smartphones and smart devices. Born from the vivo ecosystem in 2019, iQOO leverages cutting-edge R&D to deliver speed, power, and innovation to users worldwide. For more information, visit iQOO’s official website.

SINGAPORE, Aug. 27, 2025 /PRNewswire/ — The London School of Business and Finance (LSBF) Singapore Campus has entered into a landmark collaboration with the Institute of Valuers and Appraisers, Singapore (IVAS) to launch the highly regarded Chartered Valuer and Appraiser (CVA) Programme at its campuses in Malaysia and India.

The partnership was formalised at a signing ceremony during the IVAS–IVSC Business Valuation Conference 2025, witnessed by distinguished leaders including Ms. Indranee Rajah, Minister in the Prime Minister’s Office, Second Minister for Finance and Second Minister for National Development (Guest-of-Honour), Mrs. Chia-Tern Huey Min, Chief Executive, Accounting and Corporate Regulatory Authority (ACRA) as well as Mr. Lie Kok Keong, Chairperson, IVAS Council.

This marks the first time LSBF will deliver the CVA Programme outside of Singapore. By extending to Malaysia and India, both partners aim to provide finance professionals, corporate leaders, and valuation specialists in two of Asia’s fastest-growing economies with access to a globally recognised professional qualification.

The CVA Programme sets the benchmark for professional standards in valuation, strengthening consistency and credibility across capital markets, corporate transactions, and investment landscapes.

Mr. Rathakrishnan Govind, CEO, LSBF Global, said: “Valuation is increasingly vital in today’s dynamic business environment. By bringing the CVA Programme to Malaysia and India, we are giving professionals direct access to world-class training that enhances their expertise and credibility on the global stage. This partnership underscores LSBF’s mission to expand opportunities for learners across Asia and to build talent that fuels economic growth.”

Mr. Lie Kok Keong also shared, “We are delighted to see IVAS expanding the CVA Programme through this partnership with LSBF. This collaboration will strengthen business valuation standards and practices across the region and provide professionals in Malaysia and India with access to a qualification that deepens their business valuation expertise.”

About LSBF Singapore

The London School of Business & Finance (LSBF), founded in 2003 and a member of the Global University System (GUS), serves over 25,000 students across more than 40 countries. With campuses in key cities including the UK, Singapore, and Malaysia, LSBF has expanded its international footprint, particularly in Asia. LSBF Singapore campus offers over 100 programmes in business, finance, law, hospitality, and technology, and collaborate with reputable universities to provide internationally recognised qualifications. LSBF holds EduTrust certification, partners with organizations like Grab, Deloitte and ISCA, and is an ACCA Approved Learning Partner. In recognition of its future-focused approach to education, LSBF was honoured with the Singapore Business Review’s International Business Award in Education for two consecutive years – 2024 and 2025. These accolades reaffirm LSBF’s commitment to delivering quality, industry-aligned education that empowers aspiring professionals globally.

• Robust revenue growth and substantial profit improvement
• Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation

SAN FRANCISCO and SUZHOU, China, Aug. 27, 2025 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2025 interim results and major business updates.

Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: “We delivered an outstanding performance in the first half of 2025, driven by the comprehensive acceleration of our dual-engine growth model and global innovation strategy. Supported by our oncology leadership and successful commercial launch across our general biomedicine portfolio, we have expanded our product portfolio to 16 drugs and achieved a notable improvement in revenue and profitability, maintaining strong business momentum.

On the innovation front, several core pipeline candidates with global potential achieved key proof-of-concept data, and are entering global registration trials. This demonstrates the depth of Innovent’s innovation capabilities and lays a solid foundation for globalization.

We firmly believe that a clear strategic vision combined with excellent execution will continue to drive Innovent’s growth. Looking ahead, we will further consolidate our leadership in oncology, continue exploring and implementing diversified commercialization strategies across our general biomedicine product portfolio, and accelerate the global development of our next-generation innovative pipeline. Anchored by our strategic goals of achieving RMB 20 billion in product revenue by 2027 and advancing five pipeline programs into global Phase 3 trials by 2030, Innovent will continue striving to become a world-class biopharmaceutical company.”

Dual-driven revenue growth with execution excellence

Robust revenue growth and substantial profit improvement^[1]

• Total revenue: RMB 5.95 billion, up 50.6% year-on-year
• Product revenue: RMB 5.23 billion, up 37.3% year-on-year
• Net profit: RMB 1.21 billion; EBITDA: RMB 1.41 billion
• Gross margin: 86.8%, up 2.7 percentage points year-on-year
• Selling and administrative expenses ratio: 44.2%, down 7.9 percentage points year-on-year
• R&D investment: RMB 903 million
• Cash on hand: approximately USD 2 billion^[2]

Dual-engine growth supported by comprehensive and diversified product portfolio

• Expansion of oncology product portfolio with three new launches
  • Dovbleron^® (taletrectinib) : Potentially best-in-class ROS1 inhibitor
  • Limertinib: Third-generation EGFR TKI
  • Jaypirca^®(pirtobrutinib) : First non-covalent BTK inhibitor
• Strengthening general biomedicine portfolio with innovative pipeline
  • SINTBILO^® (tafolecimab injection): First PCSK-9 inhibitor successfully included in the NRDL, received approval by Macau ISAF in May 2025
  • SYCUME^® (teprotumumab N01 injection): First approved anti-IGF-1R monoclonal antibody, ending a 70-year drought of no new treatment options for thyroid eye disease (TED) in China
  • Mazdutide (GCG/GLP-1) : Globally first and only GCG/GLP-1 dual receptor agonist for weight management, with another NDA for glycemic control of T2D adults under NMPA review

Innovative commercial strategy with multi-channel coverage

• Actively responding to the national “Year of Weight Management”: Participating in the development of the weight-loss industry ecosystem, promoting the concept of scientific weight management, and advancing obesity prevention and chronic disease management
• Deepening hospital presence and academic influence: Strengthening academic coverage in public hospitals, with the GLORY-1 study published in The New England Journal of Medicine, significantly enhancing academic influence
• Innovative multi-channel coverage: Leveraging a comprehensive sales team of over 1,000 people, integrating public hospitals, retail pharmacies, online medical platforms, and private clinic networks to facilitate convenient access to medications for chronic disease patients
• Emphasizing disease education and patient management: Integrating digital tools and professional activities to establish a patient-centric disease management system, enhancing chronic disease education and patient adherence

Enhancing brand strength through the establishment of a lifecycle management system

• TYVYT^®: NDAs for renal and colorectal cancer are under regulatory review; Phase 3 study of neoadjuvant treatment in lung cancer is underway
• SYCUME^® (teprotumumab N01 injection): new Phase 3 studies in plan for inactive TED and head-to-head comparison with steroid therapy in TED
• Mazdutide (GCG/GLP-1): second NDA for glycemic control of T2D adults is under regulatory review, alongside with two new Phase 3 studies for obstructive sleep apnea (OSA) and obesity with metabolic dysfunction-associated fatty liver disease (MAFLD, head-to-head with semaglutide 2.4mg). Additional PoC studies are ongoing for adolescent obesity, metabolic dysfunction-associated steatohepatitis (MASH), heart failure with preserved ejection fraction (HFpEF), etc.
• Picankibart (IL-23p19): a potent and long-acting IL-23p19 for moderate-to-severe plaque psoriasis pending NMPA approval; Phase 3 studies are ongoing for treatment withdrawal maintenance and psoriasis with prior inadequate response to IL-17 biologics

Emerging value from globalization strategy, prioritizing novel pipeline’s global R&D

Flagship pipeline showcased at top-tier conferences, entering global registration studies

• IBI363 (PD-1/IL-2^α-bias): Unleashing potential as a next-generation IO therapy with global first-in-class design
  • Three oral presentations at ASCO highlighted breakthrough PoC data across difficult-to-treat tumors such as IO resistant cold tumors and low PD-L1 expression, demonstrating the unique advantages of dual immune activation and long-term survival benefits
  • Three pivotal studies are underway or in plan: the first global Phase 3 study is initiating in China and the U.S. to address unmet needs in IO-resistant squamous NSCLC; the first pivotal Phase 2 study in melanoma was initiated, challenging Keytruda in first-line setting; and the first Phase 3 study in late-line colorectal cancer is about to initiate
  • Continuous exploration in first-line settings and more cancer types, including first-line lung cancer, first-line colorectal cancer, neoadjuvant lung cancer, EGFR-mutated lung cancer, platinum-resistant ovarian cancer, and more
• BI343 (CLDN18.2 ADC): two registration trials in GC and PDAC; globally the first ADC to enter a Phase 3 trial in PDAC
  • First MRCT Phase 3 study of GC has been initiated in China and Japan
  • First Phase 3 study of PDAC has been initiated
  • Global MRCT of PDAC is in plan
  • NMPA CDE Breakthrough Therapy Designation (BTD) and FDA Fast-track Designation (FTD) granted
• Over 10 next-generation programs advancing into global development

• Oncology: IBI3009 (DLL3 ADC), IBI3001 (EGFR/B7H3 ADC), IBI3003 (GPRC5D/BCMA/CD3), IBI3005 (EGFR/HER3 ADC), IBI3014 (PD-L1/TROP2 ADC), IBI3020 (CEACAM5 dual-payload ADC), etc
• CVM: IBI3016 (AGT siRNA), IBI3032 (oral GLP-1), etc
• Autoimmune: IBI356 (OX40L), IBI3002 (TSLP/ IL-4Rα), etc

Hybrid models to accelerate innovation

• IBI3009 (DLL3 ADC): global rights granted to Roche, to benefit SCLC patients worldwide

Enhance global presence with broader market access

• Six products (TYVYT^®, BYVASDA^®, Pemazyre^®, Dupert^®, SINTBILO^®, SYCUME^®) have been launched in markets including Hong Kong, Macau, Taiwan, and Southeast Asia
• More launches planned Brazil, Mexico, Columbia, India, etc

Research innovation showcased at medical conferences

• Oncology pipeline: AACR, ASCO, Nature Medicine
• General biomedicine pipeline: ADA, NEJM

Facilities and manufacturing capacity adhering to high-quality standards

• 7,500 employees globally
• Global R&D centers located in the San Francisco Bay Area, Shanghai, and Suzhou
• To date, Innovent has a total of 140,000L of operational capacity, accounting for 20% of China’s total biopharmaceutical production capacity
• First manufacturing site: 60,000L antibody and ADC production capacity in operation, ensuring high-quality supply
• Second manufacturing site: first phase of 80,000L antibody production capacity in operation, for global supply and CDMO operations

Committed to responsible business practices and enhancing ESG management practices

• Over 3,000 new oncology patients begin treatment with Innovent-developed therapeutics each day, and to date, more than 5 million patients have benefited from Innovent’s innovative drugs
• Innovent has been graded ‘AAA’ rating in MSCI ESG rankings, positioning us at the forefront of the biotechnology industry
• We have supported over 200,000 patients through our dedicated patient assistance programs, with drug donations totaling RMB 3.6 billion
• Our commitment to medical philanthropy has been recognized through prestigious awards, including the “Medical Philanthropy Promoter” title and designation as a “China Philanthropic Enterprise”
• Provided over 2,200 job opportunities for recent graduates
• To date, Innovent Biologics has contributed more than RMB 6 billion in taxes and fees

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

（1）Innovent does not recommend the use of any unapproved drug (s)/indication (s).

（2）Ramucirumab (Cyramza)，Selpercatinib (Retsevmo) and Jaypirca (pirtobrutinib) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.